

Massimo G Colombo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1578942/publications.pdf>

Version: 2024-02-01

34
papers

1,484
citations

759055

12
h-index

414303

32
g-index

34
all docs

34
docs citations

34
times ranked

2107
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2022, 54, 154-163.	0.4	15
2	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
3	Editorial: global liver fat accumulation and global healthâ€”towards a sustainable development goal. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 489-490.	1.9	0
4	Adjusting Barcelona Clinic Liver Cancer Staging System to the Evolving Landscape of Hepatocellular Carcinoma: A Look to the Future. <i>Gastroenterology</i> , 2022, 162, 2106-2108.	0.6	3
5	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 234-243.	1.9	11
6	Simvastatin Prevents Liver Microthrombosis and Sepsis Induced Coagulopathy in a Rat Model of Endotoxemia. <i>Cells</i> , 2022, 11, 1148.	1.8	7
7	Lowâ€”dose aspirin reduces the risk of HBVâ€”associated HCC even when administered shortâ€”term: Too good to be true?. <i>Hepatology</i> , 2022, 76, 300-302.	3.6	2
8	Sofosbuvir and risk of estimated glomerular filtration rate decline or endâ€”stage renal disease in patients with renal impairment. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1169-1178.	1.9	8
9	Expanding the liver exposome: Should hepatologists care about air pollution?. <i>Journal of Hepatology</i> , 2022, 76, 495-497.	1.8	4
10	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
11	The Maze of Systemic Therapy for Hepatocellular Carcinoma: Did We Find the Compass?. <i>Gastroenterology</i> , 2022, 162, 1770-1772.	0.6	2
12	Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time?. <i>Gastroenterology</i> , 2021, 160, 1423-1424.	0.6	1
13	Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. <i>Saudi Journal of Gastroenterology</i> , 2021, 27, 64.	0.5	2
14	Treating paediatric hepatitis C in the era of directâ€”acting antiviral agents. <i>Liver International</i> , 2021, 41, 1189-1200.	1.9	0
15	Climbing the Everest of Lymph Nodes Staging in Cholangiocarcinoma: Close to the Peak?. <i>Gastroenterology</i> , 2021, 160, 2186-2188.	0.6	3
16	High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. <i>American Journal of Gastroenterology</i> , 2021, 116, 1896-1904.	0.2	8
17	Liver Field during Immunotherapy of Hepatocellular Carcinoma: Some Like It Hot. <i>Gastroenterology</i> , 2021, 161, 1065-1067.	0.6	1
18	Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. <i>Hepatology Communications</i> , 2021, 5, 1824-1832.	2.0	37

#	ARTICLE	IF	CITATIONS
19	Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 3091.	1.8	13
20	Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2038-2049.	0.8	3
21	Is It Time to Recommend Low-Dose Aspirin Treatment for the Prevention of Hepatocellular Carcinoma?. <i>Gastroenterology</i> , 2020, 159, 1988-1990.	0.6	1
22	NAFLD â€” sounding the alarm on a silent epidemic. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 377-379.	8.2	94
23	EASL clinical practice guidelines for the management of occupational liver diseases. <i>Liver International</i> , 2020, 40, 136-141.	1.9	10
24	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 593-602.	1.8	38
25	Hepatotoxicity of immune check point inhibitors: Approach and management. <i>Digestive and Liver Disease</i> , 2019, 51, 1074-1078.	0.4	32
26	EASL Clinical Practice Guideline: Occupational liver diseases. <i>Journal of Hepatology</i> , 2019, 71, 1022-1037.	1.8	22
27	The EASL International Liver Foundation: A growing pup with missions that are distinct yet integrated with those of its mother. <i>Journal of Hepatology</i> , 2019, 70, 339-342.	1.8	1
28	Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 190-200.	0.7	6
29	Viral hepatitis: â€œEâ€s for equitable elimination. <i>Journal of Hepatology</i> , 2018, 69, 762-764.	1.8	12
30	The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. <i>Seminars in Liver Disease</i> , 2018, 38, 181-192.	1.8	185
31	HCV therapy and risk of liver cancer recurrence: who to treat?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 392-393.	8.2	8
32	Controlling liver cancer mortality on a global scale: Still a long way to go. <i>Journal of Hepatology</i> , 2017, 67, 216-217.	1.8	8
33	Micro-elimination â€œ A path to global elimination of hepatitis C. <i>Journal of Hepatology</i> , 2017, 67, 665-666.	1.8	182
34	Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. <i>Hepatology</i> , 2011, 54, 2055-2063.	3.6	321